Showing posts with label OS. Show all posts
Showing posts with label OS. Show all posts

Wednesday, January 15, 2020

Jan 15, 2020 - Goals of Care Throughout the Cancer Experience

As we start a New Year, many people make resolutions or aspirations. We thought it the perfect time to chat about Goals of Care Throughout the Cancer Experience. We had 18 participants join us to discuss goals from initial diagnosis, through treatment and after treatment. While we will provide some sample tweets posted during the chat in response to our topic questions, you may find the complete transcript here and the analytics here. 

T1: At diagnosis, what are some of the goals for care? Patients - What were your main goals?
  • A1: I think the main goals should be 1. Clear understanding of diagnosis. 2. Clear understanding of treatment plan. 3. A comfortable rapport with the care team where all concerns, questions, and side effects can be openly discussed now and later.
  • In addition to learning everything I could - Of course my goal was a cure - for forever . But my short term goal was making to my niece’s wedding the following May.
  • T1. I didn’t understand the difference between remission and cure so had some unrealistic expectations
  • I planned to get cured of Stage 4 disease and get back to normal life!
T2: Patients - Is a specific discussion of "goals of care" something you had with your doctor? Did they help you define your goals? 
Providers - Is this a discussion that you have with your patients and, if so, how often?
  • T2: My gyn doc who tested me pretty much referred me along to other providers. My breast surgeon and I specifically discussed goals, which I appreciated. But I think I should spend more time thinking and actually write some things down. For myself and clarity in appts
  • A2: I started treatment during summer, so my oncologist asked me about my summer and vacation plans. I appreciated this! My main goal was being well enough for my brother’s birthday, a month and a half after my first surgery.
  • T2: I was in such shock at diagnosis (was told a likely cyst) that it was cancer. That was post-op day with nerve complications. I wasn’t prepared for extent/length of surgery. It felt like I was put on a treatment treadmill I couldn’t slow down.
  • T2: An actual written plan of care done together would be great. There’s a big learning curve regarding disease, treatment, maintenance & clinical trials. It’s overwhelming for a while.
  • As a provider, I think this is critically important to discuss as early as possible! Incorporating shared decision making with a patient, her provider and the family can help set realistic (and hopeful) expectations.
T3: When considering a treatment or clinical trial do you have a discussion about the research results or guideline recommendations? Do you try to match these to your/the patient's specific goals/needs?
  • A3: This is obviously a health care provider question, but I as a patient was sure to make sure my voice was heard for my treatment preferences. I also regularly ask about clinical trials and are happy to do them if is a good fit for me.
  • Treatment preferences can be important to speak up about and be sure that the "standard of care" or whatever is being offered you fits with your goals/daily life and preferences
  • I would encourage every patient to ask her provider at every treatment decision making time point if she would be eligible for a trial—often this is how we can offer exciting, new therapies (sometimes in addition to the standard of care)
  • A3 Initial DX I researched the trial I was offered and also talked to my PCP about it. When I recurred I asked for all my options then I took a month to research what option I wanted to do. I was offered a clinical trial but chose surgery then chemo. 
  • T3: #gyncsm I was interested in clinical trials, alternative/integrative approaches, things such as fasting during chemo & nutrition but those were not available (as would have been my plan). Made most of drug trials available & clinical team explained process beautifully.
  • Many gyn cancers do have treatment guidelines available from @NCCN Patients can ask if their doctor is following the guidelines and have a discussion about why a variation for your case. So much is put on patients when diagnosed
  • @ASCO has clinical practice guidelines too that can be reviewed 
T4: What are Progression Free Survival (PFS) and Overall Survival (OS)? How do these endpoints line up with individual treatment goals? with clinical trial goals?
  • Clinical trials have end points - Progression free survival or overall survival. Some trial results have better PFS but may not offer any longer overall survival
  • T4. Aaah! One of my fave topics! There is much confusion in the PARP community about OS vs PFS. Many patients want PARPs because they think they’ll live longer.
  • T4: Here's the best brief overview of the concepts of progression free survival vs. overall survival: https://www.focr.org/clinical-trial-endpoints Any of our healthcare folks have a boiled down couple sentences? So much terminology hurdles in cancer.
  • T4: From patient perspective, progression-free survival is jargon & focus on it rather than cure/survival alienating, academic or for benefit of battling drug companies. I’d always thought cure was goal of oncologists & research. Reality has been sobering/depressing.
  • @theNCI does have a Cancer Terms widget/dictionary that can be helpful https://www.cancer.gov/publications/dictionaries/cancer-terms
  • Yes. It’s not always clear what prolongs length vs. quality of life, what is done with intent to cure rather than delay recurrence, & benefits & risks of them if BRCA negative.
  • T4 providers use endpoints like progression-free survival and overall survival to understand the impact of particular treatment on the cancer... but other endpoints like patient reported outcomes (PROs), time without symptoms, quality of life may be as (or more) valuable
T5: How do goals of care change over time? Are they reassessed upon recurrence? How can readjusting goals impact treatment decisions and also daily living?
  • A5: I really think this comes down to having a good relationship with care team. A recent example: At my last appointment in December I requested my cancer follow ups to go to yearly instead of bi-yearly. I explained why and they allowed it!
  • 5. I realized after end of frontline that I might recur and have to let go of my”cure” fantasy. When I did recur, my goal was to get on a PARP at end of 2d line treatment and have me a good long remission.
  • T5: Adjusting goals is part of the process but seems bittersweet - freeing, maybe clarifying, but also tough. As mentioned, having that good relationship with your doctor where goals are part of discussions can help set clear expectations and ease readjustments...
  • Side effects impacted my treatment on recurrence so my goals had to change. As we learn more about mutations that could change our goals and treatment too.
  • A5 Right now my goal of care is to educate as many women as I can about EC and in the process heal from the scars it has left behind. I’m finding strength there and know now that You fear what you don’t understand
T6: What are some things to consider when setting patient goals for care and in communication between providers and patients about goals of care? What are your tips?
  • Care team, be honest! That is what helped me map out some of my future after my diagnosis. They didn’t tell me “you take the thyroid out and you’re done!” A line often repeated by those who don’t understand #thyroidcancer
  • It doesn’t hurt to seek outside help. There are lots of resources if you need them. Therapy, a pastor, support groups. Getting help is courageous.
  • Being sure we have access to the best and latest information on treatment for our cancer , including clinical trials is crucial in helping set goals of care.
  • @abrewi3010, in addition to advocating for goal discussions at every care interaction, suggests that patients share about themselves as a person and get to know their provider as a person. Even a couple minutes can lay foundation for working as team
  • A6 Always consider a patient’s level of support. Emotional, Physical and Financial. It has a direct relationship with compliance.
  • Great question. I think matching the care to the patient rather than the patient to the care. Being partners & collaborators & open to new ideas, possibilities & approaches.
A recent study involving survivor/advocate @Stigetta "Ovarian cancer survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum" was shared https://www.gynecologiconcology-online.net/article/S0090-8258(17)30885-5/abstract

We ended our chat, as we always do, asking for participants to share what was learned during the chat in what we call the TIL - Today I Learned. Here was one response:

TIL that goals should be discussed more at every appointment. Both care goals (exercise, diet, sticking to medication routine) and patient’s goals (school, marriage, new job, birthdays.) Once again: Communication, communication, communication!

Please join us for our next chat on February 12, 2020 at 9pmET when we will be discussing Cancer Pre-hab.

Dee
#gyncsm Co-founder

Friday, January 10, 2020

Goals of Care Throughout the Cancer Experience


Christina and I hope you will join us one week later this month on Wednesday, January 15th at 9pm ET for our chat discussing Goals of Care Throughout the Cancer Experience. We will touch upon goals of care on initial diagnosis, as well as on recurrence. We will also chat about goals when you are involved in clinical trials and the value you place on drugs that provide Progression Free Survival (PFS) but not necessarily show benefits of Overall Survival (OS).

So start off the New Year by meeting, supporting and being supported by others who have been impacted by gynecologic cancer.

Our discussion will cover the following topic areas:
  • Goals for care at diagnosis
  • Discussion of goals with care team
  • Matching goals to treatment plan
  • Endpoints - Progression Free Survival (PFS) vs. Overall Survival (OS)
  • Readjusting goals
  • Tips on setting goals for care

Also during January, which is Cervical Cancer Awareness Month, please see the website of our supporter, Cervivor for specific information about cervical cancer .

See you on the 15th.

Dee
#gyncsm Co-founder

Wednesday, July 10, 2019

Maintenance Therapies for Gyn Cancers - July 2019 Chat

This month's chat was a new but important topic for us to discuss - Maintenance Therapies for Gyn Cancers. Thank you to all our Twitter friends who promoted and joined in this chat.

We had 19 participants, including patients who have been on maintenance, advocates and physicians. You may find more analytics here and the transcript here. As always a list of resources can be found at the bottom of this page.

T1: What are maintenance therapies and why are they used?

  • @theNCI def: maintenance therapy is given to help keep cancer from coming back after it has disappeared following the initial therapy. It may include treatment with drugs, vaccines, or antibodies that kill cancer cells, and it may be given for a long time.
  • A1 Maintenance therapies are additional chemotherapy given beyond the standard chemotherapy. The philosophy is based on treatment for hematologic cancers and is now used for some solid tumors. The hope is that the additional treatment will prevent or delay recurrences.
  • The goal of maintenance therapy is to prevent recurrence or increase the time to next therapy with less side effects than chemotherapy
  • The downside of maintenance therapy is that patients may experience toxicity and a decriment in quality of life while on a maintenance program. Neuropathy was the reason that Taxol maintenance did not become a standard of care after 2 clinical trials in ovarian cancer. Also the initial benefit seen in survival was no longer apparent after patients were followed for longer time periods


T2A:  What evidence was there to approve Avastin (Bevacizumab) for maintenance?
T2B: How long is Bev given? What side effects may women experience with maintenance Bev? Is Bev limited to women with a BRCA mutation?
  • Numerous clinical trials from American and European consortiums have demonstrated benefit of bevacizumab in the maintenance setting in Gyn cancers. (Gog252)
  • FDA Approval was based on GOG-0218 a multicenter, randomized, double-blind, placebo-controlled, three-arm study w/ addition of bev to carbo Taxol for patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer
  • A2B in the US trial bevacizumab was given as maintenance for 15 cycles 3 weeks apart. Although an initial survival benefit was seen this was not sustained with longer followup. A similar trial was conducted in Europe with similar results.
  • In the maintenance phase, bevacizumab can be given up to an extra year of treatment. It is still unclear whether we should be giving this longer as no clinical trials have administered the drug longer than this. I have a personally treated patients for many years.#gyncsm
  • A2B Bevacizumab is generally well tolerated - some patients may have high blood pressure or kidney problems. More severe side effects are rare but possible.
  • Bevacizumab as maintenance is another therapy available for select women with #ovariancancer. Recommendations must be personalized to a specific patient (getting the right drug to the right patient at the right time
  • For anyone with gyn #sarcoma: Bevacizumab (Avastin) failed in a study of women with uterine #leiomyosarcoma, but some doctors are considering other combinations with it.
T3A: PARP inhibitors were approved for recurrent ovarian cancer and now for maintenance therapy for women with the BRCA mutation. What study results led to the FDA approval? 
T3B How long is PARP given during maintenance? What side effects may women experience?
  • You can get an overview of PARP inhibitors for maintenance therapy of ovarian cancer via @FacingOurRisk site https://t.co/DNA0tsgoeN
  • T3A One study used was phase III SOLO1 trial (NCT01844986) assessed maintenance olaparib/placebo treatment following first-line platinum-based chemotherapy
  • T3A Frontline maintenance olaparib treatment was approved by the FDA in December 2018 for BRCAm carriers
  • T3B: PARP truly can be used until progression, or side effects make the patients want to stop. Biggest SE I see are GI and heme (bone marrow). Some recent eye changes...which is a new one!
  • T3B the length of parp maintenance will depend on the clinical scenario (up front or recurrent) as well as the patient's tolerance to the medications
  • Clinical trials proves a 21 month progression free survival for each of the PARP inhibitors: olaparib, rucaparib
  • The treatment is generally given until either the disease progresses where the patient cannot tolerate side effect. The side effects are different among each of the agents but generally fall into the realms of low blood counts, fatigue, nausea, in general malaise.
  • Some women with gyn #leiomyosarcoma use #trabectedin (#Yondelis) as maintenance therapy. They and women with endometrial stromal #sarcoma may use hormone therapy. (I took an aromatase inhibitor for about 5 years.)
T4: Are maintenance drugs given for other gyn cancers? Cervical, endometrial, etc?
  • No maintenance strategies are currently approved for endometrial cancer but a trial evaluated carboplatin and paclitaxel for six cycles with and without trastuzumab in high-grade serous endometrial cancer with Her2/neu overexpression.The study demonstrated a significant improvement in PFS Time will tell if OS will also improve
  • T4: No maintenance for Endometrial or Cervical—Except in those with mutations that they can use Keytruda—which is “kinda of” a maintenance
  • Yes. Maintenance with bevacizumab is standard for cervical and endometrial cancers as well as ovarian/fallopian tube/primary peritoneal cancers. 
T5: What questions should a patient ask when offered a maintenance therapy? 
  • Am I a good candidate for maintenance therapy? Which maintenance therapy is best for my cancer? How will we know when is the right time to stop treatment?
  • Some I would ask include: what are the side effects of long term use of the treatment? Will I be able to use this again if I recur? How much is the cost? And will my insurance cover it?
  • Cost can be a real burden with maintenance therapies. Important to ask so that risks and benefits can be weighed.
  • Women with gyn #leiomyosarcoma should ask to see the evidence for aromatase inhibitors, not just accept anecdotal information. For example, the fact that I did it is not proof it worked.
  • At #ASCO19 @Atul_Gawande spoke on asking patients about THEIR goals. This is the key with maintenance—what does your patient want? What is their goal?
Some information shared in this chat on Maintenance therapies appeared in @ASCO Educational Book article titled Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers https://ascopubs.org/doi/full/10.1200/EDBK_238755

We hope you will join and spread the word about the all-cancer chat #CancerSM on Thursday July 11, 2019  at 8pmET on the Basics of Biomarker Testing with @TimAllenMDJD . 

Be sure to mark your calendar and join us for next month's chat Wednesday, Aug 14th on Finding Balance: “Cancer Life” vs. “Real Life”.  

Dee
#gyncsm Co-founder


RESOURCES 

Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers https://ascopubs.org/doi/full/10.1200/EDBK_238755

NCCN updates from annual conference  AJMC re: bev and parps https://www.ajmc.com/conferences/nccn-2019/nccn-ovarian-cancer-guidelines-add-options-for-parp-inhibitors-bevacizumab

Cost of maintenance therapies https://pharmaintelligence.informa.com/resources/product-content/how-ovarian-cancer-maintenance-therapies-stack-up-on-costs-and-value